Correspondence 0001213900-24-006862 from Silo Pharma, Inc. (SILO)
Silo Pharma, Inc.
Date: Jan. 26, 2024 · CIK: 0001514183 · Accession: 0001213900-24-006862
AI Filing Summary & Sentiment
Reasoning
Letter
Silo Pharma, Inc.
677 N. Washington Blvd.
Sarasota, Florida 34236
January 26, 2024
VIA EDGAR
United States Securities and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549
Attention: Bradley Ecker
Re: Silo Pharma, Inc.
Registration Statement on Form S-3
File No. 333- 276658
Ladies and Gentlemen:
Pursuant to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended, Silo Pharma, Inc. (the “Company”) respectfully requests that the effective date of the registration statement referred to above be accelerated so that it will become effective at 5:00 p.m., Eastern Standard Time, on Tuesday January 30, 2024, or as soon thereafter as possible.
Please notify Greg Carney of Sheppard, Mullin, Richter & Hampton LLP, counsel to the Company, at (213) 617-4209 as soon as possible as to the time the Registration Statement has been declared effective pursuant to this acceleration request.
SILO PHARMA, INC.
By: /s/ Eric Weisblum
Name: Eric Weisblum
Title: Chief Executive Officer
Show Raw Text
CORRESP
1
filename1.htm
Silo Pharma,
Inc.
677 N. Washington Blvd.
Sarasota, Florida 34236
January 26, 2024
VIA EDGAR
United States Securities and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549
Attention: Bradley Ecker
Re:
Silo Pharma, Inc.
Registration Statement on Form S-3
File No. 333- 276658
Ladies and Gentlemen:
Pursuant to Rule 461
of the General Rules and Regulations under the Securities Act of 1933, as amended, Silo Pharma, Inc. (the “Company”)
respectfully requests that the effective date of the registration statement referred to above be accelerated so that it will become effective
at 5:00 p.m., Eastern Standard Time, on Tuesday January 30, 2024, or as soon thereafter as possible.
Please notify Greg Carney
of Sheppard, Mullin, Richter & Hampton LLP, counsel to the Company, at (213) 617-4209 as soon as possible as to the time the Registration
Statement has been declared effective pursuant to this acceleration request.
SILO PHARMA, INC.
By:
/s/ Eric Weisblum
Name:
Eric Weisblum
Title:
Chief Executive Officer